{
    "timestamp": "Jul 7, 2025 7:12 AM EST",
    "stats": {
        "input_words": 27754,
        "output_words": 168,
        "filings_processed": 2
    },
    "filings": [
        {
            "company_name": "Molina Healthcare",
            "stock": "MOH",
            "wiki_url": "https://en.wikipedia.org/wiki/Molina_Healthcare",
            "change_percent": 0,
            "price": 239.62,
            "filing_type": "8-K",
            "filing_time": "2025-07-07T06:31:21-04:00",
            "filing_url": "https://www.sec.gov/Archives/edgar/data/1179929/000143774925022210/0001437749-25-022210-index.htm",
            "accession_number": "0001437749-25-022210",
            "summary_points": [
                "1. Molina Healthcare's preliminary second-quarter 2025 adjusted earnings per share are approximately $5.50, lower than previously anticipated due to medical cost pressures across all business lines.",
                "2.  Full-year 2025 adjusted earnings per share guidance is revised to $21.50 to $22.50, representing a consolidated pre-tax margin of just under 4%, the low end of their long-term guidance range.",
                "3.  Management attributes the short-term earnings pressure to a temporary mismatch between premium rates and medical cost trends, which recently accelerated; however, they expect this to continue into the second half of 2025."
            ]
        },
        {
            "company_name": "Dow Inc.",
            "stock": "DOW",
            "wiki_url": "https://en.wikipedia.org/wiki/Dow_Chemical_Company",
            "change_percent": 0,
            "price": 28.43,
            "filing_type": "8-K",
            "filing_time": "2025-07-07T06:03:40-04:00",
            "filing_url": "https://www.sec.gov/Archives/edgar/data/1751788/000175178825000139/0001751788-25-000139-index.htm",
            "accession_number": "0001751788-25-000139",
            "summary_points": [
                "1. Dow Inc. announced restructuring actions on June 30, 2025, resulting in anticipated charges of $630 million to $790 million, including $330 million to $360 million in asset write-downs and write-offs.",
                "2.  Future cash payments related to these restructuring actions are projected to be approximately $500 million over the next four years.",
                "3. The restructuring is expected to generate an Operating EBITDA uplift starting in 2026, reaching 50% of the ~$200 million target by the end of 2027, and fully delivering by 2029."
            ]
        }
    ]
}